Player FM uygulamasıyla çevrimdışı Player FM !
Zilebesiran - A New Hypertension Treatment
Manage episode 379944714 series 2931422
Injectable, long-acting therapy is a new frontier for hypertension management. Join host, Geoff Wall, as he evaluates zilebesiran, a hepatic angiotensinogen blocker for blood pressure control for up to six months.
The GameChanger
Zilebesiran blocks the final production of angiotensinogen at the hepatic level making it safer from a renal perspective than the ACEis or ARBs. A single subcutaneous injection provides therapy for up to six months.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20;389(3):228-238. doi: 10.1056/NEJMoa2208391. PMID: 37467498.
https://www.nejm.org/doi/full/10.1056/NEJMoa2208391
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the mechanism of action of Zilebesiran
2. Discuss possible advantages and disadvantages of this drug in the treatment of hypertension
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-323-H01-P
Initial release date: 10/16 /2023
Expiration date: 10/16/2024
Additional CPE details can be found here.
Bölümler
1. Exploring a Novel Anti-Hypertensive Drug (00:00:08)
2. Safety and Efficacy of SIRNA Drug (00:08:45)
3. Zillibeserian Drug Study for Hypertension (00:16:17)
277 bölüm
Manage episode 379944714 series 2931422
Injectable, long-acting therapy is a new frontier for hypertension management. Join host, Geoff Wall, as he evaluates zilebesiran, a hepatic angiotensinogen blocker for blood pressure control for up to six months.
The GameChanger
Zilebesiran blocks the final production of angiotensinogen at the hepatic level making it safer from a renal perspective than the ACEis or ARBs. A single subcutaneous injection provides therapy for up to six months.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20;389(3):228-238. doi: 10.1056/NEJMoa2208391. PMID: 37467498.
https://www.nejm.org/doi/full/10.1056/NEJMoa2208391
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the mechanism of action of Zilebesiran
2. Discuss possible advantages and disadvantages of this drug in the treatment of hypertension
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-323-H01-P
Initial release date: 10/16 /2023
Expiration date: 10/16/2024
Additional CPE details can be found here.
Bölümler
1. Exploring a Novel Anti-Hypertensive Drug (00:00:08)
2. Safety and Efficacy of SIRNA Drug (00:08:45)
3. Zillibeserian Drug Study for Hypertension (00:16:17)
277 bölüm
Tüm bölümler
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.